Vivoryon Therapeutics AG ( (GB:0R3M) ) just unveiled an announcement.
Vivoryon Therapeutics announced it will host a virtual R&D update on February 18, 2025, featuring presentations on the beneficial effects of varoglutamstat on kidney function and its potential market positioning. This event will offer insights into the company’s clinical development plans and provide an opportunity for investor and analyst engagement, potentially strengthening Vivoryon’s positioning in the biotech industry.
More about Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. The company leverages its expertise in post-translational modifications to develop orally available small molecule inhibitors targeting diseases such as Alzheimer’s, inflammatory and fibrotic disorders, and cancer.
YTD Price Performance: -3.22%
Average Trading Volume: 3,756
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €50.47M
See more data about 0R3M stock on TipRanks’ Stock Analysis page.